Bacterial Biosensor for Bile Salt Detection in Liver Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring liver diseases, such as hepatitis and cirrhosis, are limited by the need for sophisticated infrastructure and trained technicians, and existing biomarkers for early detection of liver dysfunction are not specific or easily scalable.
Innovation Solution
Development of a bacterial biosensor using a fusion protein that detects bile salts, specifically a VtrA polypeptide fused with a DNA binding domain, which activates expression of a detection protein in response to bile salts, allowing for sensitive and scalable detection of liver dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liver biopsy and ultrasound-based elastography are used for diagnosis, then diagnostic accuracy is improved, but infrastructure complexity and technician training requirements increase
Solution Approach 1:
The patent uses bacterial biosensors as simplified copies or alternatives to complex imaging devices. The biosensors detect liver function through biochemical reactions in simple test tubes, replicating the diagnostic capability without needing sophisticated ultrasound equipment or biopsy infrastructure.
Solution Approach 2:
The patent replaces mechanical and physical systems (ultrasound waves, surgical biopsy tools) with biochemical systems. The bacterial biosensors use enzymatic reactions and cellular metabolism to detect liver function markers, substituting complex mechanical imaging with simple chemical assays.
2Reliability
If serum enzymatic activities and bilirubin are measured, then liver function monitoring is improved, but detection timing is delayed until damage progresses
Solution Approach 1:
The patent employs bacterial biosensors that detect early markers of liver dysfunction before significant damage occurs. The sensors are designed to respond to subtle biochemical changes in serum samples, enabling preliminary detection of liver stress before enzymatic activities and bilirubin levels rise to detectable thresholds.
3Reliability
If multiple enzymatic activities are measured simultaneously, then liver function assessment is improved, but detection specificity decreases
Solution Approach 1:
The patent extracts and measures specific biochemical markers individually using bacterial biosensors, rather than measuring multiple enzymes simultaneously. This selective extraction of key markers (such as bile acids or specific metabolites) maintains detection specificity while still providing comprehensive liver function assessment through the unique profile of each marker.
4Measurement precision
If current bile salts detection methods are used, then alternative biomarker detection is improved, but scalability and practicality deteriorate
Solution Approach 1:
The patent uses living bacterial cells as self-contained detection systems. The bacteria naturally metabolize and respond to bile salts through their cellular machinery, eliminating the need for complex external detection equipment. This self-service capability allows simple incubation and direct observation, making the method highly scalable and practical for routine clinical use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables sensitive and cost-effective detection of bile salts in clinical samples, providing a scalable platform for early diagnosis and monitoring of liver diseases, suitable for point-of-care or large-scale monitoring.
Implementation Method 1
a VtrA polypeptide fused with a DNA binding domain, which activates expression of a detection protein in response to bile salts
Data Source
AI summary
Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety In of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes.